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Case study 
A 43-year old male patient with no tuberculosis (TB) clinically records was admitted to the 
Hospital Universitario General de Valencia, Spain in April of 2009. The patient did not present 
any comorbility or risk factor that supposed a bad therapeutic compliance (e.g HIV negative 
status).  The patient was first diagnosed with pulmonary TB and treated with the standard first-
line therapy for active TB (Two months with rifampicin [RIF], isoniazid [INH], ethambutol 
[EMB] and pyrazinamide [PZA], followed by four months of RIF and INH only), adjusting for 
body weight. During this period, serial sputum-positive samples was collected and culture in 
order to 1) confirm the presence of Mycobacterium tuberculosis Complex (MTBC) bacilli and 
2) to performed drug susceptibility testing (DST). MTB identification was carried out using the 
commercial kit BACTEC MGIT TBc Identification Test (Becton Dickinson and Co, Franklin 
Lakes, New Jersey). First-line DST was perfomed using rapid phenotypic BACTEC MGIT 960 
system (Becton Dickinson and Co, Franklin Lakes, New Jersey) and genotypic probes 
(GenoType MTBDR plus, Hain Lifescience, Nehren, Germany). DST results indicated that the 
isolate was fully-susceptible to all first-line antibiotics. After two months of treatment, the 
patient became sputum smear and culture negative. Consecutive negative samples for next four 
months (n=4) confirmed that the patient was cured. During 2010 and 2012 the patient presented 
negative sputum smear and was discharged. 
In September 2013, the patient was readmitted to the hospital because he presented typical TB 
symptoms suggesting a relapse episode. MTBC was detected in sputum smear samples and 
confirmed in by rapid culture-based immunoassay (BACTEC MGIT TBc Identification Test). 
Relapse disease has been related with the infection by an MDR TB strain. So, phenotypic and 
genoptypic DST was performed. Again, phenotypic DST and line-probe assays showed no 
evidence of drug resistance. With this scenario, the patient was treated with the same first-line 
antituberculous therapy maintained all effective drugs. Six months later (March 2014) the 
patient became sputum and culture-negative and once again, was considered cured. 
Unfortunately, in June 2014, a single sputum specimen was detected as an INH mono-resistant 
isolate by phenotypic BACTEC MGIT 960 system but no mutation was detected by genotypic 
Hain line-probes assay. Because the infection strains was considered INH mono-resistant and 
there were more four effective antituberculous agents, the drug remigen was prolongated 
another nine months. Notably, during this time, phenotypic DST from all the clinical culture-
positive samples tested negative for resistance to first-line drugs. Due to the first episode and 
the continuum culture-positive sputum status during the relapse, the therapy was extended until 
December 2015. As a consequence of the long and ineffective TB regimen, the patient 
developed a great cavity in the right upper lung. 
In December 2015, whole genome sequencing (WGS) was performed for a culture derived from 
a positive sputum sample of the patient isolated in June of 2014. WGS analysis identified 
mutations in the rpoB and katG genes conferring RIF and INH resistance (rpoB I491F and katG 
G273R, respectively), which indicated an infection caused by probable a multidrug resistant 
(MDR) strain. We corroborated and validated RIF and INH resistance by extensive phenotypic 
DST methods (Proportions method in the case of the RIF and REMA assay for INH, see 
Supplementary Methods for a detailed description). With this result, the antituberculois therapy 
was changed, and second-line drugs were added following the recommendations by the WHO 
guidelines[1]. This regimen included the administration of EMB, Moxifloxacin (MFX), PZA, 
higher doses of INH (INH+) and the injectable agent Capreomycin (CP). We decided to use CP 
instead of other aminoglycoside because of the greater ease of intramuscular administration. 
From this point, WGS was used in retrospective manner to genomic characterirzed all the stored 
clinical samples from the patient, since the first TB episode in 2009. In addition, WGS was used 
prospective manner toghether with hospital phenotypic DST results to guide the antibiotic 
regimen in the patient. 
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On June 2016, after six months of the MDR treatment, a new sputum smear and culture-positive 
appeared. WGS analysis of this sample revealed the presence of mutations conferring EMB, 
MFX, and high likely CP drug resistance (embB G238Y, gyrB E540D and tlyA L16R, 
respectively), indicating that TB infecting isolate had evolved to an extensively drug-resistant 
(XDR) strain. Phenotypic DST performed in the hospital (Sensititre MYCOTB MIC Plate, Trek 
Diagnostics System, Cleveland, OH) confirmed MFX drug resistance (MIC 4µg/ml) and 
susceptibility to amikacin (MIC ≤1µg/ml). Based on these findings and following the WHO 
recommendations [1], we decided to change the drug treatment in the same month adding the 
second-line amikacin and linezolid agents, INH+ and PZA. In addition, surgical intervention was 
proposed but there were several cavited foci in both lungs and the patient rejected this option. 
The last culture-positive sputum was dectected in February 2017. A year later, amikacin was 
removed from the therapy due to the patient had suffered adverse effects such as hearing and 
sigth loss.  
It is notable that PZA resistance was no detected by phenotypic (BACTEC MGIT 960 system) 
and genotypic (WGS analysis) methods during the nine years of the disease.  
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SUPPLEMENTARY METHODS 
Isolate collection and DNA extraction 
For this study, we used sixteen serial clinical isolates from a single patient and one 
epidemiologically related sample, all supplied by the Hospital General de Valencia. The single-
patient samples covered a total of 9 years and included a first episode of active TB and a relapse 
incident years later (Supplementary Table 1). Positive mycobacterial growth indicator tubes 
(MGIT) were subcultured in Middlebrook 7H11 agar plates supplemented with 10% OADC 
(Becton-Dickinson) for 5 weeks at 37°C. We scrapped bacteria with a sterile loop four times 
across the plate to obtain a representative sample of the population and we extracted their DNA 
using the CTAB protocol [2]. The rest of the bacteria was also scrapped and stored in 1ml of 
glycerol (20%) at -80 C°. Because of the high risk to manage and work with XDR strains, 
isolates G1257, G1720 and G1928 were directly extracted from the positive MGIT culture. 
Routine microbiological diagnostics methods 
 
Standard phenotypic DST for the first-line anti tuberculosis drugs (and linezolid [LZD] in one 
isolate) was performed in all clinical samples during whole study period using the BACTEC 
MGIT 960 system (Becton Dickinson and Co, Franklin Lakes, New Jersey) following the 
manufacturer recommended critical concentrations for each drug; RIF (1.0µg/ml), INH 
(0.1µg/ml), ethambutol (EMB) (5.0µg/ml), pyrazinamide (PZA) (100µg/ml), streptomycin STR 
(1.0µg/ml) and LZD (1.0µg/ml).In addition, genotypic line-probes assays for RIF and INH 
resistance was carried out with the commercial kit GenoType MTBDR plus (Hain Lifescience, 
Nehren, Germany). Finally, Sensititre MYCOTB MIC Plate (Trek Diagnostics System, 
Cleveland, OH)) was applied within a few clinical samples to determine the minimal inhibitory 
concentrations (MIC) for some second-line antibiotics such as moxifloxacin (MFX), 
ethionamide (ETH) and amikacin (AMK). The following range of concentrations were used; 
MFX, (0.06-8µg/ml); ETH, (0.3-40µg/ml); AMK, (0.12-16µg/ml). 
Whole genome sequencing analysis 
 
DNA from diagnostic cultures was extracted as previously described [3]. Sequencing libraries 
were constructed with Nextera XT DNA Library Preparation Kit (Illumina, San Diego, CA) 
following the manufacturer instructions. WGS was performed on the Illumina MiSeq instrument 
and the average sequencing depth value per base was 168-fold (range: 103-268). To account for 
contaminant DNA, we identified reads only belonging to the Mycobacterium tuberculosis 
Complex (MTBC) using KRAKEN software [4]. Mapping and single nucleotide polymorphism 
(SNP) calling was performed following a previous pipeline [5]. Briefly, MTBC reads were 
mapped and aligned to an inferred MTBC most likely common ancestor genome using BWA 
[6]. Next, we separated variants into INDELS (small insertions and deletions included) and 
SNPs. Single polymorphisms with at least 10 reads in both strands and a quality score of 20 
were selected and classified into two categories based on their frequency in the sample. We 
considered fixed SNPs those with no less than 90% of frequency and low-frequency SNPs those 
involving variants whose frequencies range between 10 and 89%. An INDEL was considered 
whether the mutation was present with a minimum deep coverage of 10x. SNP annotation was 
performed using H37Rv annotation reference (AL123456.2). Finally, SNPs annotated in regions 
difficult to map such as repetitive sequences and PPE/PE-PGRS genes were removed from the 
analysis as well as those detected near INDELS. 
Identification of relapse versus re-infection strains 
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In order to identify whether the isolates from the first and second disease episode were the same 
(relapse) or coming from two independent infections (re-infection) we applied both a 
phylogenetic and a SNP threshold approach. Regarding the SNP threshold approach, pairwise 
genetic distances were compared based on a concatenated SNP alignment obtained from every 
fixed SNP from every isolate. A genetic distance below 12 SNPs is indicative of clonal 
diversification from the first episode strain and thus is classified as a relapse case. On the 
contrary distances beyond 12 SNPs are indicative of exogenous infection with a different strain 
and thus the case is classified as likely re-infection [7,8]. To differentiate phylogenetically 
between relapse and re-infection we built a phylogeny including all the isolates from the first 
and second episode as well as epidemiological related sample (brother). The phylogeny was 
inferred following maximum likelihood phylogenetic approach using RAxML v8.2 [9] applying 
the General Time Reversible model of nucleotide substitution with the Gamma distribution 
(GTRGAMMA).  
Identification of known lineage and drug resistance associated mutations 
Once we had determined all the polymorphic sites (including fixed and variable SNPs), we 
compared our SNP and INDEL data with a series of publicly available predictive databases 
(Phyresse [10], Mykrobe predictor [11], TB-profiler [12], latest accessed on April 2018) to 
determine lineage and drug resistance mutations present in our samples. Isolates were classified 
as susceptible, resistant or multidrug resistant (MDR) according to the mutations identified. 
 
Identification of candidate drug resistance variants 
Relevant variants during the course of treatment were selected if they appeared at least in one 
isolate with a minimum frequency of 15% and had at least 15% of difference between any two 
isolates (n=96, see Supplementary Table 2). Global frequency of the new candidate mutations 
was evaluated against a database of 4,762 genomes collected world-wide. The same database 
was used to identify strains with and without “disputed” rpoB mutations as well as new drug 
resistance determinants to INH in katG gene. 
Isolation of single colonies and drug susceptibility testing of new drug resistance mutations 
After the identification of a series of novel mutations in genes or genomic regions associated 
with drug resistance we decided to explicitly test if those mutations conferred resistance by 
phenotypically and genetically characterizing a series of single-colony isolates. Twenty-two 
single colonies from six clinical samples with different co-existing haplotypes were isolated 
from Middlebrook 7H11 agar plates, grown for 10 to 15 days in Middlebrook 7H9 at 37C and 
stored in 500µl aliquotes with 20% glycerol at -80 C° until used. 
Antibiotic stock solutions were prepared at 10 mg/ml either in sterile water (INH) or methanol 
(RIF, both from Sigma-Aldrich) and stored at -20ºC. Nine days before the experiments, 500µl 
of frozen inoculum from each of the 22 colonies were cultured in 10ml of Middlebrook 7H9 
broth supplemented with 10% ADC (Becton-Dickinson) and 0.1% tween80. Exponentially-
growing bacteria were adjusted to an optical density of 0.2 (which is equivalent to a 1 
McFarcland turbidity standard) in tween-free Middlebrook 7H9 broth immediately prior to use. 
We obtained the MIC for INH following the resazurin microtiter assay (REMA) protocol [13]. 
Briefly, serial two-fold dilutions ranging from 0.125 to 32µg/ml of INH in tween-free 7H9 broth 
were prepared in a 96-well plate, with a volume of 100µl. We then added 100µl of a 1:100 
dilution of a fresh density adjusted bacterial suspension, prepared as above and sealed the plate 
in a hermetic plastic bag. Because of the slow growth of the samples carried the rpob I491F 
mutations, after 9 days of incubation at 37°C, 30µl of 0.02% resazurin was added to each well 
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and the plate was further incubated at 37ºC for 48 h. A change of color from blue to pink 
indicates bacterial growth. The MIC was defined as the lowest drug concentration that 
prevented this color change. Drug and bacteria free wells were used as control.  
To determine phenotypic resistance to RIF, we used the proportion method (PM) in 
Middlebrook 7H11 agar according to standard procedures [14]. The reason for using this 
particular method is that these strains grow very slowly in RIF-containing broth and give 
inconsistent results with the REMA. In brief, 50µl of a 10-2 and a 10-4 dilutions of a fresh 
density-adjusted bacterial suspension were cultured in plates containing 0.125 to 64µg/ml of 
RIF. Drug-free plates were used as a positive control. After 3 weeks of incubation at 37°C, the 
number of colonies forming units growing on medium with antibiotic were compared with those 
on the positive control. The proportion of resistant bacteria was represented as percentage. The 
MIC was defined as the first drug concentration where there was no growth.  
The H37Rv strain was used as a quality control in all experiments. In addition, the isolate from 
the first episode that is wild-type (G1480) for the mutations was used to measure the increase on 
MIC in the following isolates. Strains were classified as susceptible or resistant according to the 
critical concentrations recommended by WHO (guidelines 2012). 
Deep amplicon sequencing: amplification, library construction and sequencing 
In order to confirm the SNPs identified and the possible detection of additional very low-
frequency variants (<5%), we performed deep amplicon sequencing following and adjusting the 
single molecule-overlapping reads (SMOR) approach [15]. Six primer sets were designed to 
target specific regions of rpoB, katG and ahpC (promoter and CDS included) (see 
supplementary Table 5), producing amplicons between 285-339bp. We used two additional 
primers sets targeting phylogenetic lineage-diagnostic SNPs as internal controls. A total of 39 
samples were analysed including 15 clinical isolates from the case, 22 from single colonies and 
two controls (lineage 4 H37Ra and a Lineage 2 Beijing strain). A single PCR amplification step 
was carried out with parameters: initial denaturation at 95ºC for 3min, 20 cycles of denaturation 
at 98ºC for 15 sec, annealing at 65ºC for 15s and extension at 72ºC for 30s, with a final 
extension at 72ºC for 2min. Each reaction contained 12.5µl of 2x KAPA HiFi HotStart 
ReadyMix (KAPA biosystems), 0.75µl of 10µM forward primer, 0.75µl of 10µM reverse 
primer, 5 µl of template DNA and 6µl of PCR-grade water. After amplification, reactions were 
pooled by sample (5µl of each amplicon and 20µl of 10µM Tris-HCl) and purified using 1X 
NucleoMag NGS Clean-up and Size Select (Macherey-Nagel) up to 50µl final volume. 
Amplicon sequencing libraries construction and sequencing were performed as described for 
whole genome sequencing. Purified libraries were validated on a Bioanalyzer DNA chip 
(Agilent Technologies) to verify fragment size, and quantified using Qubit 3.0 Fluorometer 
(Thermo Fisher Scientific). The expected average coverage for this experiment was 50,000 fold 
per base. 
Data availability 
All genomic data are deposited in the European Nucleotide Archive under the Bioproject 
numbers PRJEB22237 and PRJEB25887. 
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SUPLEMENTARY RESULTS 
 
Non-canonical resistance mutations can lead to under-reporting and treatment of MDR-
TB cases 
The fact that INH resistance went undetected (likely due to the fitness cost of the RIF mutation 
on replication [16] led us to question whether non-canonical (also known as “disputed”) 
mutations are involved in a systematic under detection of MDR-TB. We pooled together a 
global SNP database of 4762 strains. A total of 66 strains harbored a non-canonical RIF 
resistance mutation (7.6% of the strains with a RIF resistance mutation). Of these, only 24 
isolates contained a known katG mutation as opposed to 92.4% in strains carrying undisputed 
RIF resistance mutations (36%, P<0.001, chi-square test). Some of the strains could be  RIF 
mono-resistant, particularly related with relapse cases [17,18]. However, we hypothesized that 
a percentage of these strains were undetected MDR cases associated to non-canonical 
mutations. Among strains with a “non-canonical” rpoB mutation we found seven mutations not 
described before, all of them leading to an aminoacid change. For three of them we had 
evidence of convergent evolution, a strong predictor of resistance particularly in drug resistance 
associated regions [19,20]. One, katG V1A have been recently identified as INH associated 
with resistance [21]. For the other two (V473L and G285V), publicly available phenotypic 
results are contradictory as the majority of the isolates were susceptible. However, rpoB I491F 
mutation was present in four out of the six strains indicating a possible parallelism with the 
phenotyping problems presented in this manuscript.   
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SUPPLEMENTARY FIGURES 
Supplementary Figure 1. Management of the case and role of the genomic and clinical 
laboratories. 
Timeline with the most relevant patient’s management clinical events during 9 years of the 
infection. The clinical laboratory (red line) refers to the routine BACTEC-MGIT (phenotypic) 
and Hain Gentotype MTBDRplus (genotypic) assays performed in the hospital. The genomic 
laboratory (green lines) corresponds to results obtained by whole genome sequencing analysis 
of the isolates and available from 2015 onwards. Once the relevant mutations were identified 
using WGS individual clones at different time-points were isolated and tested for RIF and INH 
resistance using an alternative approach to BACTEC MGIT. WGS was also used in a 
prospective manner to predict DST to new drugs during MDR-TB treatment. 
  
 12
Supplementary Figure 2. Genetic relationship between all the isolates. Sample G1480 
corresponds to the first episode and presented a fully-susceptible resistance profile; G1479 
corresponds to the first relapse isolate. A. Inferred maximum Likelihood tree. Isolates G1720, 
G1721 and G1928 presented an extensively drug-resistant profile. B. Pairwise SNP distanced 
between all samples. 
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Supplementary Figure 3. Predicted percentage of the susceptible (grey bar) versus INH 
resistant populations (blue bar) identified across all isolates. 
The percentage of the INH resistant population refers to the sum of the frequencies of the two 
INH mutations co-existing in the patient (katG G273 and G249del).  
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SUPPLEMENTARY TABLES 
Supplementary Table 1. List of loci associated with drug resistance used to predict resistance profile. 
Genomic 
position 
Wild-type
allele 
Mutation 
allele 
Genomic
Region 
Gene 
Name 
Gene
Alias 
Gene 
Direction 
Amino acid 
Change 
Codon
Change 
Antibiotic SNP 
Confidence* 
6575 C T coding Rv0005 gyrB + Arg446Cys cgt/tgt FQ Low confidence 
6620 G C coding Rv0005 gyrB + Asp461His gac/cac FQ High confidence 
6620 G A coding Rv0005 gyrB + Asp461Asn gac/aac FQ High confidence 
6621 A C coding Rv0005 gyrB + Asp461Ala gac/gcc FQ High confidence 
6734 A G coding Rv0005 gyrB + Asn499Asp aac/gac FQ High confidence 
6735 A C coding Rv0005 gyrB + Asn499Thr aac/acc FQ High confidence 
6736 C G coding Rv0005 gyrB + Asn499Lys aac/aag FQ High confidence 
6737 A C coding Rv0005 gyrB + Thr500Pro acc/ccc FQ High confidence 
6738 C A coding Rv0005 gyrB + Thr500Asn acc/aac FQ High confidence 
6741 A T coding Rv0005 gyrB + Glu501Val gaa/gta FQ High confidence 
6742 A T coding Rv0005 gyrB + Glu501Asp gaa/gat FQ High confidence 
6749 G A coding Rv0005 gyrB + Ala504Thr gcg/acg FQ Low confidence 
6750 C T coding Rv0005 gyrB + Ala504Val gcg/gtg FQ High confidence 
7563 G T coding Rv0006 gyrA + Gly88Cys ggc/tgc FQ High confidence 
7564 G C coding Rv0006 gyrA + Gly88Ala ggc/gcc FQ High confidence 
7566 G A coding Rv0006 gyrA + Asp89Asn gac/aac FQ Low confidence 
7570 C T coding Rv0006 gyrA + Ala90Val gcg/gtg FQ High confidence 
7572 T C coding Rv0006 gyrA + Ser91Pro tcg/ccg FQ High confidence 
7581 G C coding Rv0006 gyrA + Asp94His gac/cac FQ High confidence 
7581 G A coding Rv0006 gyrA + Asp94Asn gac/aac FQ High confidence 
7581 G T coding Rv0006 gyrA + Asp94Tyr gac/tac FQ High confidence 
7582 A G coding Rv0006 gyrA + Asp94Gly gac/ggc FQ High confidence 
7582 A C coding Rv0006 gyrA + Asp94Ala gac/gcc FQ High confidence 
7582 A T coding Rv0006 gyrA + Asp94Val gac/gtc FQ Low confidence 
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575729 C T coding Rv0486 mshA + Gln128STOP cag/tag ETH Low confidence 
576164 C T coding Rv0486 mshA + Arg273Cys cgc/tgc ETH Low confidence 
576242 G T coding Rv0486 mshA + Gly299Cys ggc/tgc ETH Low confidence 
576338 C T coding Rv0486 mshA + Gln331STOP cag/tag ETH Low confidence 
576414 G A coding Rv0486 mshA + Gly356Asp ggc/gac ETH Low confidence 
576429 A C coding Rv0486 mshA + Glu361Ala gag/gcg ETH Low confidence 
760314 G T coding Rv0667 rpoB + Val170Phe gtc/ttc RIF High confidence 
761004 A G coding Rv0667 rpoB + Thr400Ala acc/gcc RIF Low confidence 
761093 G C coding Rv0667 rpoB + Gln429His cag/cac RIF Low confidence 
761095 T C coding Rv0667 rpoB + Leu430Pro ctg/ccg RIF Low confidence 
761095 T G coding Rv0667 rpoB + Leu430Arg ctg/cgg RIF Low confidence 
761098 G T coding Rv0667 rpoB + Ser431Ile agc/atc RIF Low confidence 
761098 G C coding Rv0667 rpoB + Ser431Thr agc/acc RIF Low confidence 
761100 C A coding Rv0667 rpoB + Gln432Lys caa/aaa RIF Low confidence 
761101 A T coding Rv0667 rpoB + Gln432Leu caa/cta RIF High confidence 
761101 A C coding Rv0667 rpoB + Gln432Pro caa/cca RIF Low confidence 
761108 G T coding Rv0667 rpoB + Met434Ile atg/att RIF Low confidence 
761109 G T coding Rv0667 rpoB + Asp435Tyr gac/tac RIF High confidence 
761110 A G coding Rv0667 rpoB + Asp435Gly gac/ggc RIF High confidence 
761110 A T coding Rv0667 rpoB + Asp435Val gac/gtc RIF High confidence 
761111 C G coding Rv0667 rpoB + Asp435Glu gac/gag RIF Low confidence 
761120 C G coding Rv0667 rpoB + Asn438Lys aac/aag RIF Low confidence 
761128 C T coding Rv0667 rpoB + Ser441Leu tcg/ttg RIF Low confidence 
761128 C G coding Rv0667 rpoB + Ser441Trp tcg/tgg RIF Low confidence 
761139 C A coding Rv0667 rpoB + His445Asn cac/aac RIF High confidence 
761139 C G coding Rv0667 rpoB + His445Asp cac/gac RIF High confidence 
761139 C T coding Rv0667 rpoB + His445Tyr cac/tac RIF High confidence 
761140 A C coding Rv0667 rpoB + His445Pro cac/ccc RIF High confidence 
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761140 A G coding Rv0667 rpoB + His445Arg cac/cgc RIF High confidence 
761140 A T coding Rv0667 rpoB + His445Leu cac/ctc RIF Low confidence 
761141 C A coding Rv0667 rpoB + His445Gln cac/caa RIF Low confidence 
761154 T G coding Rv0667 rpoB + Ser450Ala tcg/gcg RIF Low confidence 
761155 C G coding Rv0667 rpoB + Ser450Trp tcg/tgg RIF High confidence 
761155 C T coding Rv0667 rpoB + Ser450Leu tcg/ttg RIF High confidence 
761161 T C coding Rv0667 rpoB + Leu452Pro ctg/ccg RIF High confidence 
761277 A T coding Rv0667 rpoB + Ile491Phe atc/ttc RIF High confidence 
781687 A G coding Rv0682 rpsL + Lys43Arg aag/agg RIF High confidence 
781821 A C coding Rv0682 rpsL + Lys88Gln aag/cag RIF Low confidence 
781822 A G coding Rv0682 rpsL + Lys88Arg aag/agg RIF High confidence 
801268 T C coding Rv0701 rplC + Cys154Arg tgt/cgt LZD Low confidence 
1472337 C T ribosomal MTB000019 rrs + --- - STR Low confidence 
1472358 C T ribosomal MTB000019 rrs + --- - STR Low confidence 
1472359 A C ribosomal MTB000019 rrs + --- - STR Low confidence 
1472362 C T ribosomal MTB000019 rrs + --- - STR Low confidence 
1472750 C A ribosomal MTB000019 rrs + --- - STR Low confidence 
1472751 A G ribosomal MTB000019 rrs + --- - STR Low confidence 
1472752 A T ribosomal MTB000019 rrs + --- - STR Low confidence 
1473246 A G ribosomal MTB000019 rrs + --- - AMK, KAN, CM High confidence 
1473247 C T ribosomal MTB000019 rrs + --- - AMK, KAN, CM High confidence 
1473329 G T ribosomal MTB000019 rrs + --- - AMK, KAN, CM High confidence 
1475956 G T ribosomal MTB000020 rrl + --- - LZD Low confidence 
1476471 G T ribosomal MTB000020 rrl + --- - LZD Low confidence 
1673423 G T intergenic Rv1483 fabG1 + --- - INH Low confidence 
1673424 A G intergenic Rv1483 fabG1 + --- - INH Low confidence 
1673425 C T intergenic Rv1483 fabG1 + --- - INH High confidence 
1673432 T A intergenic Rv1483 fabG1 + --- - INH High confidence 
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1673432 T C intergenic Rv1483 fabG1 + --- - INH High confidence 
1674481 T G coding Rv1484 inhA + Ser94Ala tcg/gcg INH, ETH High confidence 
1674782 T C coding Rv1484 inhA + Ile194Thr atc/acc INH, ETH Low confidence 
1833909 A C coding Rv1630 rpsA + Asp123Ala gac/gcc PZA Low confidence 
1834325 G A coding Rv1630 rpsA + Val262Met gtg/atg PZA Low confidence 
1917946 C T coding Rv1694 tlyA + Arg3STOP cga/tga CM Low confidence 
1917979 C T coding Rv1694 tlyA + Arg14Trp cgg/tgg CM Low confidence 
1917991 C T coding Rv1694 tlyA + Arg18STOP cga/tga CM Low confidence 
1918003 C T coding Rv1694 tlyA + Gln22STOP cag/tag CM Low confidence 
1918139 C A coding Rv1694 tlyA + Ala67Glu gcg/gag CM Low confidence 
1918144 A G coding Rv1694 tlyA + Lys69Glu aaa/gaa CM Low confidence 
1918211 C A coding Rv1694 tlyA + Ala91Glu gca/gaa CM Low confidence 
1918292 T C coding Rv1694 tlyA + Leu118Pro ctg/ccg CM Low confidence 
1918322 T A coding Rv1694 tlyA + Val128Glu gtg/gag CM Low confidence 
1918388 T C coding Rv1694 tlyA + Leu150Pro ctg/ccg CM Low confidence 
1918487 C T coding Rv1694 tlyA + Pro183Leu ccg/ctg CM Low confidence 
1918489 C A coding Rv1694 tlyA + Gln184Lys cag/aag CM Low confidence 
1918489 C T coding Rv1694 tlyA + Gln184STOP cag/tag CM Low confidence 
1918494 T G coding Rv1694 tlyA + Phe185Leu ttt/ttg CM Low confidence 
1918651 G A coding Rv1694 tlyA + Glu238Lys gag/aag CM Low confidence 
2102240 G A coding Rv1854c ndh - Arg268His cgc/cac INH, ETH Low confidence 
2102715 A G coding Rv1854c ndh - Thr110Ala acc/gcc INH, ETH Low confidence 
2155167 C G coding Rv1908c katG - Ser315Arg agc/agg INH Low confidence 
2155167 C A coding Rv1908c katG - Ser315Arg agc/aga INH Low confidence 
2155168 G C coding Rv1908c katG - Ser315Thr agc/acc INH High confidence 
2155168 G A coding Rv1908c katG - Ser315Asn agc/aac INH High confidence 
2155168 G T coding Rv1908c katG - Ser315Ile agc/atc INH High confidence 
2155169 A G coding Rv1908c katG - Ser315Gly agc/ggc INH High confidence 
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2155206 C G coding Rv1908c katG - Ser302Arg agc/agg INH Low confidence 
2155212 G C coding Rv1908c katG - Trp300Cys tgg/tgc INH Low confidence 
2155214 T G coding Rv1908c katG - Trp300Gly tgg/ggg INH High confidence 
2155222 G T coding Rv1908c katG - Gly297Val ggc/gtc INH Low confidence 
2155289 A C coding Rv1908c katG - Thr275Pro acc/ccc INH High confidence 
2155699 A G coding Rv1908c katG - Asn138Ser aac/agc INH Low confidence 
2288683 T C coding Rv2043c pncA - STOP187Arg tga/cga PZA High confidence 
2288697 T C coding Rv2043c pncA - Leu182Ser ttg/tcg PZA High confidence 
2288703 T C coding Rv2043c pncA - Val180Ala gtc/gcc PZA High confidence 
2288703 T G coding Rv2043c pncA - Val180Gly gtc/ggc PZA High confidence 
2288704 G T coding Rv2043c pncA - Val180Phe gtc/ttc PZA Low confidence 
2288718 T C coding Rv2043c pncA - Met175Thr atg/acg PZA High confidence 
2288719 A G coding Rv2043c pncA - Met175Val atg/gtg PZA High confidence 
2288727 T C coding Rv2043c pncA - Leu172Pro ctg/ccg PZA Low confidence 
2288730 C T coding Rv2043c pncA - Ala171Val gcg/gtg PZA Low confidence 
2288740 A C coding Rv2043c pncA - Thr168Pro acc/ccc PZA High confidence 
2288752 T C coding Rv2043c pncA - Ser164Pro tcg/ccg PZA High confidence 
2288754 T C coding Rv2043c pncA - Val163Ala gtg/gcg PZA High confidence 
2288757 G A coding Rv2043c pncA - Gly162Asp ggt/gat PZA Low confidence 
2288761 G C coding Rv2043c pncA - Ala161Pro gcg/ccg PZA High confidence 
2288764 A C coding Rv2043c pncA - Thr160Pro aca/cca PZA High confidence 
2288766 T G coding Rv2043c pncA - Leu159Arg ctg/cgg PZA Low confidence 
2288772 T C coding Rv2043c pncA - Val157Ala gtg/gcg PZA High confidence 
2288772 T G coding Rv2043c pncA - Val157Gly gtg/ggg PZA High confidence 
2288778 T G coding Rv2043c pncA - Val155Gly gtg/ggg PZA High confidence 
2288779 G A coding Rv2043c pncA - Val155Met gtg/atg PZA High confidence 
2288782 A G coding Rv2043c pncA - Arg154Gly agg/ggg PZA Low confidence 
2288805 C T coding Rv2043c pncA - Ala146Val gcg/gtg PZA High confidence 
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2288805 C A coding Rv2043c pncA - Ala146Glu gcg/gag PZA Low confidence 
2288806 G C coding Rv2043c pncA - Ala146Pro gcg/ccg PZA High confidence 
2288806 G A coding Rv2043c pncA - Ala146Thr gcg/acg PZA Low confidence 
2288817 C A coding Rv2043c pncA - Thr142Lys acg/aag PZA High confidence 
2288817 C T coding Rv2043c pncA - Thr142Met acg/atg PZA High confidence 
2288818 A G coding Rv2043c pncA - Thr142Ala acg/gcg PZA High confidence 
2288820 A C coding Rv2043c pncA - Gln141Pro cag/ccg PZA Low confidence 
2288821 C T coding Rv2043c pncA - Gln141STOP cag/tag PZA Low confidence 
2288823 G C coding Rv2043c pncA - Arg140Pro cgc/ccc PZA High confidence 
2288826 T G coding Rv2043c pncA - Val139Gly gtg/ggg PZA High confidence 
2288827 G C coding Rv2043c pncA - Val139Leu gtg/ctg PZA High confidence 
2288828 T G coding Rv2043c pncA - Cys138Trp tgt/tgg PZA High confidence 
2288830 T C coding Rv2043c pncA - Cys138Arg tgt/cgt PZA High confidence 
2288832 A G coding Rv2043c pncA - His137Arg cat/cgt PZA High confidence 
2288832 A C coding Rv2043c pncA - His137Pro cat/cct PZA High confidence 
2288833 C G coding Rv2043c pncA - His137Asp cat/gat PZA High confidence 
2288836 G A coding Rv2043c pncA - Asp136Asn gat/aat PZA Low confidence 
2288836 G T coding Rv2043c pncA - Asp136Tyr gat/tat PZA Low confidence 
2288838 C A coding Rv2043c pncA - Thr135Asn acc/aac PZA High confidence 
2288839 A C coding Rv2043c pncA - Thr135Pro acc/ccc PZA High confidence 
2288841 C T coding Rv2043c pncA - Ala134Val gcc/gtc PZA High confidence 
2288844 T C coding Rv2043c pncA - Ile133Thr att/act PZA Low confidence 
2288847 G C coding Rv2043c pncA - Gly132Ala ggt/gct PZA High confidence 
2288847 G A coding Rv2043c pncA - Gly132Asp ggt/gat PZA High confidence 
2288848 G T coding Rv2043c pncA - Gly132Cys ggt/tgt PZA High confidence 
2288848 G A coding Rv2043c pncA - Gly132Ser ggt/agt PZA Low confidence 
2288853 T C coding Rv2043c pncA - Val130Ala gtg/gcg PZA High confidence 
2288853 T G coding Rv2043c pncA - Val130Gly gtg/ggg PZA High confidence 
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2288857 G T coding Rv2043c pncA - Asp129Tyr gat/tat PZA High confidence 
2288859 T G coding Rv2043c pncA - Val128Gly gtc/ggc PZA Low confidence 
2288868 T G coding Rv2043c pncA - Val125Gly gtc/ggc PZA High confidence 
2288869 G T coding Rv2043c pncA - Val125Phe gtc/ttc PZA High confidence 
2288874 G C coding Rv2043c pncA - Arg123Pro cgc/ccc PZA High confidence 
2288880 G C coding Rv2043c pncA - Arg121Pro cgg/ccg PZA High confidence 
2288883 T A coding Rv2043c pncA - Leu120Gln ctg/cag PZA High confidence 
2288883 T C coding Rv2043c pncA - Leu120Pro ctg/ccg PZA High confidence 
2288883 T G coding Rv2043c pncA - Leu120Arg ctg/cgg PZA Low confidence 
2288885 G A coding Rv2043c pncA - Trp119STOP tgg/tga PZA Low confidence 
2288886 G C coding Rv2043c pncA - Trp119Ser tgg/tcg PZA High confidence 
2288886 G A coding Rv2043c pncA - Trp119STOP tgg/tag PZA High confidence 
2288887 T C coding Rv2043c pncA - Trp119Arg tgg/cgg PZA High confidence 
2288887 T G coding Rv2043c pncA - Trp119Gly tgg/ggg PZA High confidence 
2288895 T G coding Rv2043c pncA - Leu116Arg ctg/cgg PZA High confidence 
2288895 T C coding Rv2043c pncA - Leu116Pro ctg/ccg PZA High confidence 
2288902 A C coding Rv2043c pncA - Thr114Pro acg/ccg PZA Low confidence 
2288920 G A coding Rv2043c pncA - Gly108Arg gga/aga PZA High confidence 
2288920 G C coding Rv2043c pncA - Gly108Arg gga/cga PZA High confidence 
2288928 G A coding Rv2043c pncA - Gly105Asp ggc/gac PZA High confidence 
2288930 C A coding Rv2043c pncA - Ser104Arg agc/aga PZA High confidence 
2288931 G T coding Rv2043c pncA - Ser104Ile agc/atc PZA High confidence 
2288933 C G coding Rv2043c pncA - Tyr103STOP tac/tag PZA High confidence 
2288934 A G coding Rv2043c pncA - Tyr103Cys tac/tgc PZA High confidence 
2288934 A C coding Rv2043c pncA - Tyr103Ser tac/tcc PZA Low confidence 
2288935 T G coding Rv2043c pncA - Tyr103Asp tac/gac PZA High confidence 
2288938 G A coding Rv2043c pncA - Ala102Thr gcg/acg PZA High confidence 
2288944 A G coding Rv2043c pncA - Thr100Ala acc/gcc PZA High confidence 
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2288944 A C coding Rv2043c pncA - Thr100Pro acc/ccc PZA High confidence 
2288945 C A coding Rv2043c pncA - Tyr99STOP tac/taa PZA High confidence 
2288952 G C coding Rv2043c pncA - Gly97Ala ggt/gct PZA High confidence 
2288952 G A coding Rv2043c pncA - Gly97Asp ggt/gat PZA High confidence 
2288953 G A coding Rv2043c pncA - Gly97Ser ggt/agt PZA Low confidence 
2288954 G A coding Rv2043c pncA - Lys96Asn aag/aac PZA High confidence 
2288955 A G coding Rv2043c pncA - Lys96Arg aag/agg PZA High confidence 
2288955 A C coding Rv2043c pncA - Lys96Thr aag/acg PZA High confidence 
2288956 A C coding Rv2043c pncA - Lys96Gln aag/cag PZA High confidence 
2288956 A G coding Rv2043c pncA - Lys96Glu aag/gag PZA Low confidence 
2288957 C G coding Rv2043c pncA - Tyr95STOP tac/tag PZA High confidence 
2288960 C A coding Rv2043c pncA - Phe94Leu ttc/tta PZA High confidence 
2288960 C G coding Rv2043c pncA - Phe94Leu ttc/ttg PZA High confidence 
2288961 T G coding Rv2043c pncA - Phe94Cys ttc/tgc PZA High confidence 
2288961 T C coding Rv2043c pncA - Phe94Ser ttc/tcc PZA High confidence 
2288962 T C coding Rv2043c pncA - Phe94Leu ttc/ctc PZA High confidence 
2288971 G T coding Rv2043c pncA - Glu91STOP gag/tag PZA High confidence 
2288982 C T coding Rv2043c pncA - Thr87Met acg/atg PZA Low confidence 
2288988 T G coding Rv2043c pncA - Leu85Arg ctg/cgg PZA High confidence 
2288988 T C coding Rv2043c pncA - Leu85Pro ctg/ccg PZA Low confidence 
2288997 A G coding Rv2043c pncA - His82Arg cat/cgt PZA High confidence 
2288998 C G coding Rv2043c pncA - His82Asp cat/gat PZA High confidence 
2289000 T G coding Rv2043c pncA - Phe81Cys ttc/tgc PZA High confidence 
2289000 T C coding Rv2043c pncA - Phe81Ser ttc/tcc PZA High confidence 
2289001 T G coding Rv2043c pncA - Phe81Val ttc/gtc PZA High confidence 
2289016 A C coding Rv2043c pncA - Thr76Pro act/cct PZA Low confidence 
2289028 T C coding Rv2043c pncA - Cys72Arg tgc/cgc PZA High confidence 
2289029 T A coding Rv2043c pncA - His71Gln cat/caa PZA High confidence 
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2289030 A G coding Rv2043c pncA - His71Arg cat/cgt PZA High confidence 
2289031 C T coding Rv2043c pncA - His71Tyr cat/tat PZA Low confidence 
2289036 C T coding Rv2043c pncA - Pro69Leu cca/cta PZA Low confidence 
2289038 G C coding Rv2043c pncA - Trp68Cys tgg/tgc PZA High confidence 
2289038 G T coding Rv2043c pncA - Trp68Cys tgg/tgt PZA High confidence 
2289039 G A coding Rv2043c pncA - Trp68STOP tgg/tag PZA High confidence 
2289039 G C coding Rv2043c pncA - Trp68Ser tgg/tcg PZA Low confidence 
2289040 T C coding Rv2043c pncA - Trp68Arg tgg/cgg PZA Low confidence 
2289040 T G coding Rv2043c pncA - Trp68Gly tgg/ggg PZA Low confidence 
2289043 T C coding Rv2043c pncA - Ser67Pro tcg/ccg PZA High confidence 
2289050 T G coding Rv2043c pncA - Tyr64STOP tat/tag PZA High confidence 
2289052 T G coding Rv2043c pncA - Tyr64Asp tat/gat PZA Low confidence 
2289054 A G coding Rv2043c pncA - Asp63Gly gac/ggc PZA Low confidence 
2289057 C T coding Rv2043c pncA - Pro62Leu ccg/ctg PZA High confidence 
2289061 A C coding Rv2043c pncA - Thr61Pro aca/cca PZA Low confidence 
2289068 C A coding Rv2043c pncA - Phe58Leu ttc/tta PZA High confidence 
2289068 C G coding Rv2043c pncA - Phe58Leu ttc/ttg PZA High confidence 
2289070 T C coding Rv2043c pncA - Phe58Leu ttc/ctc PZA High confidence 
2289071 C G coding Rv2043c pncA - His57Gln cac/ag  PZA High confidence 
2289072 A G coding Rv2043c pncA - His57Arg cac/cgc PZA High confidence 
2289072 A C coding Rv2043c pncA - His57Pro cac/ccc PZA High confidence 
2289073 C G coding Rv2043c pncA - His57Asp cac/gac PZA Low confidence 
2289073 C T coding Rv2043c pncA - His57Tyr cac/tac PZA Low confidence 
2289081 C G coding Rv2043c pncA - Pro54Arg ccg/cgg PZA High confidence 
2289081 C A coding Rv2043c pncA - Pro54Gln ccg/cag PZA High confidence 
2289081 C T coding Rv2043c pncA - Pro54Leu ccg/ctg PZA Low confidence 
2289082 C T coding Rv2043c pncA - Pro54Ser ccg/tcg PZA High confidence 
2289089 C A coding Rv2043c pncA - His51Gln cac/caa PZA High confidence 
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2289090 A G coding Rv2043c pncA - His51Arg cac/cgc PZA High confidence 
2289090 A C coding Rv2043c pncA - His51Pro cac/ccc PZA High confidence 
2289091 C T coding Rv2043c pncA - His51Tyr cac/tac PZA High confidence 
2289096 A C coding Rv2043c pncA - Asp49Ala gac/gcc PZA Low confidence 
2289096 A G coding Rv2043c pncA - Asp49Gly gac/ggc PZA Low confidence 
2289097 G A coding Rv2043c pncA - Asp49Asn gac/aac PZA High confidence 
2289100 A G coding Rv2043c pncA - Lys48Glu aag/gag PZA High confidence 
2289100 A T coding Rv2043c pncA - Lys48STOP aag/tag PZA High confidence 
2289103 A C coding Rv2043c pncA - Thr47Pro acc/ccc PZA High confidence 
2289103 A G coding Rv2043c pncA - Thr47Ala acc/gcc PZA Low confidence 
2289108 T G coding Rv2043c pncA - Val45Gly gtg/ggg PZA Low confidence 
2289111 T G coding Rv2043c pncA - Val44Gly gtc/ggc PZA High confidence 
2289133 G T coding Rv2043c pncA - Glu37top gaa/taa PZA High confidence 
2289138 T C coding Rv2043c pncA - Leu35Pro ctg/ccg PZA High confidence 
2289140 C G coding Rv2043c pncA - Tyr34STOP tac/tag PZA High confidence 
2289150 T G coding Rv2043c pncA - Ile31Ser atc/agc PZA High confidence 
2289159 C A coding Rv2043c pncA - Ala28Asp gcc/gac PZA Low confidence 
2289162 T C coding Rv2043c pncA - Leu27Pro ctg/ccg PZA High confidence 
2289171 G A coding Rv2043c pncA - Gly24Asp ggc/gac PZA High confidence 
2289180 T G coding Rv2043c pncA - Val21Gly gta/gga PZA High confidence 
2289186 T C coding Rv2043c pncA - Leu19Pro ctg/ccg PZA High confidence 
2289193 G A coding Rv2043c pncA - Gly17Ser ggc/agc PZA High confidence 
2289200 C A coding Rv2043c pncA - Cys14STOP tgc/tga PZA High confidence 
2289201 G A coding Rv2043c pncA - Cys14Tyr tgc/tac PZA Low confidence 
2289202 T C coding Rv2043c pncA - Cys14Arg tgc/cgc PZA High confidence 
2289203 C G coding Rv2043c pncA - Phe13Leu ttc/ttg PZA High confidence 
2289204 T C coding Rv2043c pncA - Phe13Ser ttc/tcc PZA Low confidence 
2289206 C G coding Rv2043c pncA - Asp12Glu gac/gag PZA High confidence 
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2289207 A C coding Rv2043c pncA - Asp12Ala gac/gcc PZA High confidence 
2289208 G A coding Rv2043c pncA - Asp12Asn gac/aac PZA Low confidence 
2289213 A G coding Rv2043c pncA - Gln10Arg cag/cgg PZA Low confidence 
2289213 A C coding Rv2043c pncA - Gln10Pro cag/ccg PZA Low confidence 
2289214 C A coding Rv2043c pncA - Gln10Lys cag/aag PZA High confidence 
2289216 T C coding Rv2043c pncA - Val9Ala gtg/gcg PZA Low confidence 
2289216 T G coding Rv2043c pncA - Val9Gly gtg/ggg PZA Low confidence 
2289218 C A coding Rv2043c pncA - Asp8Glu gac/gaa PZA High confidence 
2289219 A C coding Rv2043c pncA - Asp8Ala gac/gcc PZA High confidence 
2289219 A G coding Rv2043c pncA - Asp8Gly gac/ggc PZA Low confidence 
2289220 G A coding Rv2043c pncA - Asp8Asn gac/aac PZA High confidence 
2289222 T G coding Rv2043c pncA - Val7Gly gtc/ggc PZA High confidence 
2289222 T A coding Rv2043c pncA - Val7Asp gtc/gac PZA Low confidence 
2289223 G T coding Rv2043c pncA - Val7Phe gtc/ttc PZA High confidence 
2289225 T C coding Rv2043c pncA - Ile6Thr atc/acc PZA High confidence 
2289231 T G coding Rv2043c pncA - Leu4Ser ttg/tcg PZA High confidence 
2289231 T G coding Rv2043c pncA - Leu4Trp ttg/tgg PZA Low confidence 
2289234 C A coding Rv2043c pncA - Ala3Glu gcg/gag PZA High confidence 
2289235 G C coding Rv2043c pncA - Ala3Pro gcg/ccg PZA Low confidence 
2289239 G A coding Rv2043c pncA - Met1Ile atg/ata PZA High confidence 
2289239 G T coding Rv2043c pncA - Met1Ile atg/att PZA Low confidence 
2289240 T A coding Rv2043c pncA - Met1Lys atg/aag PZA High confidence 
2289240 T C coding Rv2043c pncA - Met1Thr atg/acg PZA High confidence 
2289248 T C intergenic Rv2043c pncA - --- - PZA High confidence 
2289248 T G intergenic Rv2043c pncA - --- - PZA High confidence 
2289252 A G intergenic Rv2043c pncA - --- - PZA High confidence 
2289252 A C intergenic Rv2043c pncA - --- - PZA High confidence 
2289252 A T intergenic Rv2043c pncA - --- - PZA High confidence 
 25
2715342 G A intergenic Rv2416c eis - --- - KAN Low confidence 
2715346 C T intergenic Rv2416c eis - --- - KAN Low confidence 
2726136 C T intergenic Rv2428 ahpC + --- - INH Low confidence 
2726145 G A intergenic Rv2428 ahpC + --- - INH Low confidence 
3073808 C G coding Rv2764c thyA - Arg222Gly cgc/ggc PAS Low confidence 
4241078 A G coding Rv3793 embC + Ile406Val atc/gtc EMB Low confidence 
4243221 C T intergenic Rv3794 embA + --- - EMB Low confidence 
4243225 C A intergenic Rv3794 embA + --- - EMB Low confidence 
4243242 G A coding Rv3794 embA + Asp4Asn gac/aac EMB Low confidence 
4243245 G A coding Rv3794 embA + Gly5Ser ggt/agt EMB Low confidence 
4243833 G A coding Rv3794 embA + Ala201Thr gcg/acg EMB Low confidence 
4244193 G A coding Rv3794 embA + Gly321Ser ggc/agc EMB Low confidence 
4244281 G A coding Rv3794 embA + Gly350Asp ggc/gac EMB Low confidence 
4244617 C T coding Rv3794 embA + Ala462Val gcg/gtg EMB Low confidence 
4245730 A C coding Rv3794 embA + Asp833Ala gac/gcc EMB Low confidence 
4246734 T G coding Rv3795 embB + Leu74Arg ctg/cgg EMB Low confidence 
4247402 T G coding Rv3795 embB + Ser297Ala tcg/gcg EMB Low confidence 
4247429 A G coding Rv3795 embB + Met306Val atg/gtg EMB High confidence 
4247429 A C coding Rv3795 embB + Met306Leu atg/ctg EMB High confidence 
4247430 T C coding Rv3795 embB + Met306Thr atg/acg EMB High confidence 
4247431 G A coding Rv3795 embB + Met306Ile atg/ata EMB High confidence 
4247431 G C coding Rv3795 embB + Met306Ile atg/atc EMB High confidence 
4247431 G T coding Rv3795 embB + Met306Ile atg/att EMB High confidence 
4247469 A C coding Rv3795 embB + Tyr319Ser tat/tct EMB Low confidence 
4247495 G T coding Rv3795 embB + Asp328Tyr gat/tat EMB Low confidence 
4247496 A G coding Rv3795 embB + Asp328Gly gat/ggt EMB Low confidence 
4247507 T C coding Rv3795 embB + Trp332Arg tgg/cgg EMB Low confidence 
4247513 T C coding Rv3795 embB + Tyr334His tac/cac EMB Low confidence 
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4247573 G A coding Rv3795 embB + Asp354Asn gac/aac EMB Low confidence 
4247717 C G coding Rv3795 embB + Leu402Val ctg/gtg EMB Low confidence 
4247723 C T coding Rv3795 embB + Pro404Ser ccg/tcg EMB Low confidence 
4247729 G A coding Rv3795 embB + Gly406Ser ggc/agc EMB High confidence 
4247729 G T coding Rv3795 embB + Gly406Cys ggc/tgc EMB High confidence 
4247730 G C coding Rv3795 embB + Gly406Ala ggc/gcc EMB High confidence 
4247730 G A coding Rv3795 embB + Gly406Asp ggc/gac EMB High confidence 
4247863 C G coding Rv3795 embB + Ile450Met atc/atg EMB Low confidence 
4247873 G A coding Rv3795 embB + Ala454Thr gcg/acg EMB Low confidence 
4248002 C A coding Rv3795 embB + Gln497Lys cag/aag EMB Low confidence 
4248003 A G coding Rv3795 embB + Gln497Arg cag/cgg EMB High confidence 
4248747 G A coding Rv3795 embB + Gly745Asp ggc/gac EMB Low confidence 
4249518 A G coding Rv3795 embB + His1002Arg cac/cgc EMB Low confidence 
4326087 C A coding Rv3854c ethA - Arg463Ser cgt/agt ETH Low confidence 
4326236 G A coding Rv3854c ethA - Gly413Asp ggt/gat ETH Low confidence 
4326300 A G coding Rv3854c ethA - Thr392Ala acg/gcg ETH Low confidence 
4326320 G A coding Rv3854c ethA - Gly385Asp ggc/gac ETH Low confidence 
4326333 G C coding Rv3854c ethA - Ala381Pro gcc/ccc ETH Low confidence 
4326449 C A coding Rv3854c ethA - Thr342Lys acg/aag ETH Low confidence 
4326461 T G coding Rv3854c ethA - Ile338Ser atc/agc ETH Low confidence 
4326738 C T coding Rv3854c ethA - Gln246STOP cag/tag ETH Low confidence 
4326807 G A coding Rv3854c ethA - Glu223Lys gag/aag ETH Low confidence 
4326917 C A coding Rv3854c ethA - Thr186Lys acg/aag ETH Low confidence 
4327224 T G coding Rv3854c ethA - Tyr84Asp tac/gac ETH Low confidence 
4327301 A C coding Rv3854c ethA - Asp58Ala gac/gcc ETH Low confidence 
4327307 A C coding Rv3854c ethA - Asp56Ala gac/gcc ETH Low confidence 
4327322 C T coding Rv3854c ethA - Pro51Leu ccc/ctc ETH Low confidence 
4327346 G A coding Rv3854c ethA - Gly43Asp ggc/gac ETH Low confidence 
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4327347 G T coding Rv3854c ethA - Gly43Cys ggc/tgc ETH Low confidence 
4407604 C A coding Rv3919c gidB - Ala200Glu gcg/gag STR Low confidence 
4407790 C T coding Rv3919c gidB - Ala138Val gcg/gtg STR Low confidence 
4407824 C T coding Rv3919c gidB - Gln127STOP caa/taa STR Low confidence 
4407931 T C coding Rv3919c gidB - Leu91Pro cta/cca STR Low confidence 
4407940 T C coding Rv3919c gidB - Val88Ala gta/gca STR Low confidence 
4407992 G A coding Rv3919c gidB - Gly71Arg gga/aga STR Low confidence 
4408009 T G coding Rv3919c gidB - Val65Gly gtc/ggc STR Low confidence 
4408102 G C coding Rv3919c gidB - Gly34Ala ggg/gcg STR Low confidence 
* Confidence of the variant. High confidence means that variant has a statistical significant value, while Low confidence does not. The list was obtained by PhyResSe 
available database[10] (latest accessed in April 2018).   
Abbreviations: AMK, amikacin; CM, capreomycin; FQ, fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin); EMB, ethambutol; ETH, ethionamide; INH, isoniazid; 
KAN, kanamycin; LZD, linezolid; STR, streptomycin; PAS, para-aminosalicylic acid; PZA, pyrazinamide. 
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Supplementary Table 2. Significant variant frequencies across all isolates 
Genomic 
Position 
Wild-type
Allele 
Variant 
Allele 
Jan 
2014 
March
2014 
June 
2014 
Aug 
2014 
Oct 
2014 
Dec 
2014 
Jan 
2015 
April
2015 
June 
2015 
Nov 
2015 
Dec 
2015 
June 
2016 
Oct 
2016 
Jan 
2017 
6742 A C 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 100% 100% 100% 
36471 C G 0% 0% 57.14% 0% 0% 0% 0% 0% 0% 0% 60% 0% 0% 0% 
80564 C G 0% 0% 0% 0% 0% 0% 0% 0% 14.58% 0% 0% 0% 0% 0% 
130660 T A 100% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
208321 C Ga 0% 0% 0% 0% 0% 0% 0% 0% 0% 85.71% 0% 0% 0% 0% 
232974 A C 0% 0% 0% 0% 0% 0% 0% 93.33% 85.35% 28.22% 0% 0% 0% 0% 
580797 A G 0% 0% 0% 0% 0% 0% 0% 0% 0% 66.67% 0% 0% 33.33% 0% 
623273 G A 0% 0% 0% 0% 100% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
650379 C T 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
699980 G C 0% 0% 0% 15% 0% 55.56% 0% 0% 0% 0% 0% 0% 0% 0% 
725302 C T 0% 20.93% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
761152 T A 0% 0% 0% 0% 11.82% 0% 0% 7.25% 0% 0% 0% 0% 0% 6.41% 
761277 A T 100% 100% 99.24% 99.56% 99.07% 99.32% 100% 100% 98.63% 98.97% 100% 98.97% 100% 99.32% 
851731 T G 0% 0% 0% 0% 23.48% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
852638 C G 0% 0% 0% 0% 0% 50.81% 71.91% 0% 0% 0% 0% 0% 0% 0% 
854253 C G 0% 0% 0% 30.77% 0% 0% 0% 0% 27.27% 0% 0% 0% 0% 0% 
916546 G T 0% 0% 0% 0% 0% 19.05% 0% 0% 0% 0% 0% 0% 0% 0% 
939197 G C 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
1002273 G A 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 98.37% 100% 100% 
1131770 C T 0% 0% 0% 0% 14.97% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
1157076 C A 100% 100% 99.25% 98.97% 100% 100% 99.07% 100% 99.35% 100% 100% 100% 100% 100% 
1230842 T C 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 99.19% 99.64% 100% 
1474752 T C 100% 100% 100% 98.68% 95.83% 97.83% 100% 95.65% 100% 100% 98.04% 100% 100% 99.49% 
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1502314 C T 99.48% 100% 100% 100% 100% 100% 100% 100% 100% 98.35% 100% 99.05% 100% 100% 
1514788 G T 0% 25.66% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
1519823 A G 0% 0% 0% 0% 0% 0% 0% 0% 100% 75% 0% 0% 0% 0% 
1524571 A T 0% 0% 0% 100% 0% 0% 0% 0% 100% 100% 100% 0% 75% 0% 
1543413 C G 0% 0% 0% 0% 0% 0% 0% 0% 37.50% 0% 0% 0% 0% 0% 
1917986 T G 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 99.08% 98.07% 100% 
1960078 C A 0% 0% 0% 0% 0% 0% 0% 84.47% 0% 0% 0% 0% 0% 0% 
1997457 G C 0% 0% 0% 36.36% 0% 0% 0% 0% 20% 20% 0% 0% 27.78% 0% 
2074547 G T 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 100% 0% 
2094917 T A 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 21.43% 0% 
2154827 C - 99.00% 0% 0% 0% 67% 41% 38% 0% 8% 71% 93% 72% 98% 97% 
2155295 C G 0% 98.06% 40.74% 97.14% 24.39% 52.21% 65.08% 95.89% 82.95% 28.32% 0% 0% 0% 0% 
2180818 T C 0% 0% 0% 0% 0% 0% 0% 0% 0% 80% 0% 0% 0% 0% 
2183360 C T 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 49.07% 0% 0% 
2262857 C T 100% 100% 100% 100% 100% 100% 100% 100% 0% 100% 100% 100% 100% 100% 
2300456 G A 0% 0% 0% 0% 0% 0% 0% 0% 0% 51.97% 0% 0% 0% 0% 
2304044 T A 0% 0% 0% 0% 0% 0% 0% 0% 0% 19.85% 0% 0% 0% 0% 
2314650 T C 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
2339605 A G 100% 100% 90.91% 100% 100% 100% 0% 100% 100% 100% 100% 0% 100% 0% 
2363682 C A 0% 0% 0% 100% 0% 0% 100% 0% 0% 100% 0% 0% 100% 0% 
2370345 C T 0% 0% 0% 0% 0% 0% 52% 0% 0% 0% 0% 0% 0% 0% 
2482657 G C 0% 0% 21.05% 36.17% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
2525723 G C 20% 0% 0% 0% 0% 0% 0% 0% 0% 17.39% 0% 0% 0% 0% 
2527757 C T 0% 0% 23.27% 36.18% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
2534563 G C 30% 0% 75% 0% 27.27% 0% 0% 0% 0% 33.33% 0% 0% 0% 0% 
2536917 T C 0% 16.39% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
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2542966 C T 0% 0% 0% 0% 0% 60% 0% 0% 0% 0% 0% 0% 0% 0% 
2551675 A C 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 100% 0% 0% 0% 
2726112 C T 0% 0% 19.77% 35.34% 0% 25.83% 0% 96.72% 0% 0% 0% 21.78% 0% 0% 
2726139 C T 0% 0% 13.79% 67.91% 0% 26% 0% 0% 0% 0% 0% 0% 0% 0% 
2726141 C A/T 0% 5.71% 0% 0% 0% 0% 45.19% 0% 0% 0% 0% 0% 0% 0% 
2726145 G A 0% 0% 0% 0% 0% 0% 0% 0% 0% 7.52% 64.93% 0% 0% 0% 
2726153 G A 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 7% 0% 0% 0% 
2726767 A C 94.94% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
2786787 T G 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 75% 0% 0% 0% 
2794585 C A 100% 100% 100% 100% 99.32% 100% 100% 100% 100% 100% 100% 100% 100% 100% 
2879778 G T 100% 100% 97.22% 99.02% 100% 98.41% 100% 100% 100% 100% 98.15% 92.86% 98.91% 97.87% 
2895066 C G 0% 0% 0% 0% 0% 0% 0% 96.30% 82.96% 30.65% 0% 0% 0% 0% 
2895750 G A 0% 0% 0% 0% 75% 40.58% 41.73% 0% 16.34% 66.83% 97.47% 100% 100% 100% 
3007115 C A 0% 0% 0% 66.67% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
3007143 T A 0% 0% 100% 0% 0% 0% 0% 0% 0% 0% 0% 0% 100% 0% 
3007407 C G 0% 0% 0% 0% 0% 0% 0% 0% 30.25% 0% 0% 0% 0% 0% 
3008814 C T 15.85% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
3008839 G T 0% 34.78% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
3045144 C T 0% 0% 0% 0% 0% 0% 0% 0% 0% 64.52% 81.82% 100% 100% 100% 
3096287 G C 100% 100% 0% 100% 0% 100% 0% 0% 0% 0% 0% 0% 0% 0% 
3096295 G C 0% 0% 100% 100% 0% 0% 0% 75% 0% 80% 100% 75% 0% 100% 
3160000 A C 71.43% 0% 60% 87.50% 0% 100% 80% 50% 0% 71.43% 85.71% 0% 87.50% 0% 
3173107 G A 100% 100% 100% 100% 100% 98.23% 100% 100% 98.65% 99.40% 100% 100% 100% 100% 
3247866 C A 0% 0% 0% 0% 0% 0% 0% 0% 0% 60% 0% 0% 0% 0% 
3247867 A G 80% 0% 0% 0% 0% 0% 0% 0% 0% 60% 0% 0% 0% 0% 
3247868 A G 100% 0% 0% 0% 0% 42.86% 0% 0% 0% 0% 0% 0% 0% 0% 
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3247869 A G 100% 0% 0% 0% 0% 66.67% 0% 0% 60% 0% 0% 0% 0% 0% 
3349257 T C 0% 0% 0% 0% 16.28% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
3415194 G A 0% 0% 0% 0% 0% 0% 22.22% 0% 16.13% 16.13% 0% 30.77% 13.16% 0% 
3498811 A G 0% 0% 0% 0% 0% 0% 0% 0% 20.67% 0% 0% 0% 0% 0% 
3580637 T C 62.50% 0% 0% 0% 50% 50% 0% 0% 0% 0% 0% 0% 0% 0% 
3596631 G A 0% 0% 0% 0% 0% 0% 0% 0% 14.97% 0% 0% 0% 0% 0% 
3664945 C T 99.17% 100% 99.40% 100% 98.90% 99.12% 100% 96.84% 100% 100% 99.37% 100% 100% 100% 
3854063 G T 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 30% 0% 
3862473 A G 0% 0% 0% 71.43% 77.78% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
3878567 G C 0% 28.57% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 16.67% 23.53% 
3915436 C T 0% 0% 0% 0% 0% 57.14% 61.90% 0% 0% 0% 0% 0% 0% 0% 
4026874 T C 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
4117169 C G 0% 60% 0% 50% 50% 66.67% 0% 37.50% 0% 54.55% 55.56% 50% 0% 75% 
4247429 A G 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 10.26% 0% 0% 0% 
4247495 G T 0% 0% 0% 0% 0% 0% 0% 0% 0% 54.97% 88.82% 100% 100% 100% 
4255385 C G 0% 0% 0% 0% 0% 0% 0% 0% 0% 62.84% 86.62% 100% 100% 100% 
4269341 C T 0% 0% 0% 0% 0% 0% 0% 97.03% 86.79% 23.53% 0% 0% 0% 0% 
4338596 T G 0% 0% 0% 50% 40% 0% 50% 0% 0% 0% 50% 0% 21.43% 0% 
4353414 G C 100% 0% 0% 100% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
4358702 A G 71.43% 0% 0% 0% 100% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
4373008 T C 0% 0% 0% 0% 42.86% 0% 0% 0% 0% 60% 0% 0% 33.33% 0% 
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Supplementary Table 3. Isolate sequencing results and main drug resistance associated mutations 
Isolate Date Accesion number 
Mean  
coverage MTBC (%)
a 
Predicted 
resistance 
profile 
Genetic changes associated to resistance mutations 
rpoB katG oxyR-ahpCb ahpC ubiA embB gyrB tlyA 
G1480 27/04/2009 ERS1880079 171.36 99.95 DS WT WT WT WT WT WT WT WT 
G1479 20/09/2013 ERS1880078 134.25 99.87 RR I491F WT WT WT WT WT WT WT 
G516 21/01/2014 ERS1880086 212.10 99.94 MDR I491F P429del WT K192T WT WT WT WT 
G520 17/03/2014 ERS1880087 134.72 99.96 MDR I491F G273R G-6A WT WT WT WT WT 
C-10T 
G249 27/06/2014 ERS1880084 184.85 99.91 MDR I491F G273R G-6A WT WT WT WT WT 
C-12T 
C-39T 
G252 11/08/2014 ERS1880085 206.85 99.97 MDR I491F G273R C-12T WT WT WT WT WT 
C-39T 
G535 13/10/2014 ERS1880088 122.67 99.89 MDR I491F P429del WT WT WT WT WT WT 
L449Q G273R 
G841 09/12/2014 ERS1880089 162.37 99.93 MDR I491F P429del G-9A WT WT WT WT WT 
G273R C-12T 
C-39T 
G842 27/01/2015 ERS1880090 115.82 99.97 MDR I491F P429del C-10T WT WT WT WT WT 
G273R 
G993 15/04/2015 ERS1880091 137.62 99.77 MDR I491F G273R C-39T WT G165S WT WT WT 
L449Q 
G1003 11/06/2015 ERS1880075 186.61 99.95 MDR I491F P429del WT WT G165S WT WT WT 
G273R 
G1257 09/11/2015 ERS1880076 268.63 99.90 MDR I491F P429del G-6A WT G165S D328Y WT WT 
G273R 
G1478 11/12/2015 ERS1880077 151.24 99.91 MDR I491F P429del G-6A WT WT D328Y WT WT 
M306V 
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G1720 02/06/2016 ERS1880081 118.75 99.97 XDR I491F P429del G-9A WT WT D328Y E540D L16R 
C-10T 
C-39T 
G1721 14/10/2016 ERS1880082 249.21 99.75 XDR I491F P429del WT WT WT D328Y E540D L16R 
I491F 
G1928 09/01/2017 ERS1880083 201.00 99.66 XDR L449Q P429del C-39T WT WT D328Y E540D L16R 
a Percentage of reads belonging to MTBC. 
b Promoter mutations between oxyR and ahpc genes. 
Abbreviations: DS, drug susceptible; MDR, multidrug resistance; MTBC, Mycobacterium tuberculosis Complex; XDR, extensively drug-resistant. 
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Supplementary Table 4. Drug resistance associated variants identified in this study 
Drug 
associated 
Genomic 
position 
Wild type 
allele 
Mutant  
alelle 
Gene 
alias 
Gene 
name 
Gene 
type 
Mutation 
type 
Nucleotide
change 
Aminoacid 
change 
Moxifloxacin 6742 A C gyrB Rv0005 essential nonsynonymous A1620C E540D 
Rifampicin 761152 T A rpoB Rv0667 essential nonsynonymous A1346T L449Q 
Rifampicin 761277 A T rpoB Rv0667 essential nonsynonymous A1471T I491F 
Capreomycin 1917986 T G tlyA Rv1694 nonessential nonsynonymous T47G L16R 
Isoniazid 2154827 C - katG Rv1908c nonessential nonsynonymous C1285Δ G429del 
Isoniazid 2155295 C G katG Rv1908c nonessential nonsynonymous G817C G273R 
Isoniazid 2726112 C T ahpC promoter mutation 
Isoniazid 2726139 C T ahpC promoter mutation 
Isoniazid 2726141 C A/T ahpC promoter mutation 
Isoniazid 2726145 G A ahpC promoter mutation 
Isoniazid 2726153 G A ahpC promoter mutation 
Isoniazid 2726767 A C ahpC Rv2428 nonessential nonsynonymous A575C K192T 
Ethambutol 4247429 A G embB Rv3795 essential nonsynonymous A916G M306V 
Ethambutol 4247495 G T embB Rv3795 essential nonsynonymous G982T D328Y 
Ethambutol 4269341 C T ubiA Rv3806c essential nonsynonymous G493A G165S 
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Supplementary Table 5. Drug resistance profile predicted by publicly databases 
a Based on WGS data. 
c Predicted whole-genome-based DST (WGS-DST) using publicly available software and after this study 
Abbreviations: DS, drug susceptible; MDR, multidrug resistance; RR, rifampicin resistant; XDR, extensively drug-resistance. 
  
Isolate Date 
Predicted 
resistance type 
(this study)a 
Predicted WGS-DST Rifampicin/Isoniazidb 
PhyResSe[10] Mykrobe 
 predictor[11] 
TB 
profiler[12] 
G1480 27/04/2009 DS -/- -/- -/- 
G1479 20/09/2013 RR +/- -/- +/- 
G516 21/01/2014 MDR +/- -/- +/- 
G520 17/03/2014 MDR +/- -/- +/- 
G249 27/06/2014 MDR +/- -/- +/- 
G252 11/08/2014 MDR +/- -/- +/- 
G535 13/10/2014 MDR +/- -/- +/- 
G841 09/12/2014 MDR +/- -/- +/- 
G842 27/01/2015 MDR +/- -/- +/- 
G993 15/04/2015 MDR +/- -/- +/- 
G1003 11/06/2015 MDR +/- -/- +/- 
G1257 09/11/2015 MDR +/- -/- +/- 
G1478 11/12/2015 MDR +/- -/- +/- 
G1720 02/06/2016 XDR +/- -/- +/- 
G1721 14/10/2016 XDR +/- -/- +/- 
G1928 09/01/2017 XDR +/- -/- +/- 
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Supplementary Table 6. Primers used for amplicon sequencing of relevant rpoB, katG and ahpC regions 
Amplicon target* Primer sequences Product  length (bp)** 
 
Reference 
rpoB RRDR 
 (761020-761233) 
5-CGATCACACCGCAGACGTT-3 
232 
 
[15] 
5-GTTTCGATCGGGCACATCC-3  
rpoB 491 
(761126-761362) 
5-GTCGGGGTTGACCCACAAG-3 
256 
 
This study 
5-CAGGTACACGATCTCGTCGC-3  
katG 315 
(2155074-2155345) 
5-CCATGAACGACGTCGAAACAG-3 
272 
 
[15] 
5-GCTCTTCGTCAGCTCCCACTC-3  
katG 429del  
(2154941-2154723) 
5-AGACAGTCAATCCCGATGCC-3 
257 
 
This study 
5-GCGGGTGGATCCGATCTATG-3  
oxyR-ahpC promoter 
(2726015-2726251) 
5-ACCACTGCTTTGCCGCCACC-3 
236 
 
[22] 
5-CCGATGAGAGCGGTGAGCTG-3  
ahpC 192  
(2726608-2726856) 
5-ACCCCAACAACGAGATCCAG-3 
218 
 
This study 
5-GATGTCTTTGGCGTACTCGG-3  
*Positions correspond to H37Rv genome. NCBI Reference Sequence NC_000962.3 
**Length includes Illumina adapter sequences 
Abbreviations:  RRDR, rifampicin-resistance-determining-region
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